Lacritin was discovered, named and characterized by the founder at the University of Virginia.
An unbiased screen for natural factors that promote tear protein release led to the identification of a novel gene product from the human lacrimal and salivary glands that as a recombinant protein was highly potent in releasing tears, and was named lacritin.
Strong IP was developed. Patents have been issued in the US, Europe, Japan and Canada.
With the University of Virginia lead, lacritin has been rigorously developed and tested at multiple institutions through the US and Canada.
Lacritin is downregulated in 95% of patients with aqueous deficient dry eye.
- Lacritin is a natural human tear protein
- Reported to be downregulated in 95% of patients
with aqueous deficient dry eye eg. Sjrogren's Syndrome.
- Stimulates basal tearing (topical; preclinical)
- Protects the surface of the corneal epithelium from
inflammatory cytokines (topical; preclinical)
- Reduces lacrimal gland inflammation (topical;
- Active as a peptide mimetic that is soluble and can
be readily synthesized
- Founded on >10 yrs of National Eye Institute
- Dry eye is the most common eye disease, affecting 5-7% of general population, increasing to 6-9.8% in
postmenopausal women and 34% in the elderly
- Most common complaint of 125 M contact lens
- Increasing awareness of dry eye as a progressive
disease in the aging US population
- Only marketed prescription drug for dry eye is
Restasis (cyclosporine). 2012 sales: ~$800 M
- Topical cyclosporine is widely recognized as
- Multibillion dollar market
- As a first in class natural tear replacement
therapy, lacritin addresses dry eye upstream of
the inflammatory sequelae
- Currently capitalizing to take through phase II
human clinical trials using an outsourcing model
- Most dry eye trials only take weeks